The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world clinical efficacy of epidermal growth factor receptor inhibitors (EGFRi) in patients with early-onset (eo), metastatic colorectal cancer (mCRC).
 
Hideaki Bando
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Toshihiro Misumi
No Relationships to Disclose
 
Harlan Pittell
Employment - Flatiron Health
 
Dionne Ng
Employment - Flatiron Health
 
Eri Tajima
Employment - Flatiron Health
 
Trevor Joseph Royce
Employment - ArteraAI; Flatiron Health
Stock and Other Ownership Interests - Lumata Health; mPATH; Roche; SonoVascular; VitriVax
Consulting or Advisory Role - Agilix Health
 
Ivy Altomare
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
 
Prashni Paliwal
Employment - Flatiron Health
 
Yoshihiro Aoyagi
No Relationships to Disclose
 
Kazuya Mizuguchi
No Relationships to Disclose
 
Motoko Suzuki
No Relationships to Disclose
 
Yuriko Takeda
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Genomedia (Inst); Molecular Health (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
Atsushi Ohtsu
Employment - AstraZeneca (I); Celgene (I)
Honoraria - Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb